Fondazione Italiana Linfomi - ETS

Alessandria, IT

OncologyCAR-TPhase II

What changed

Phase II trial registered: Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy

7mo agoTrial registeredDec 8, 2025Source filing (opens the source filing in a new tab)

Momentum

74no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

1,260 pre-ticker oncology companies at Phase II

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
Study registered
Dec 9, 2024
Marginal Zone Lymphoma(MZL) · RECRUITING · sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna · Study to Assess Effectiveness and Safety of Zanubrutinib for Patients With Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)
ClinicalTrials.gov · NCT06823960 (opens the source filing in a new tab)
Trial
PHASE2 registered
May 23, 2024
Hodgkin Lymphoma · RECRUITING · sponsor: Fondazione Italiana Linfomi - ETS · Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy
ClinicalTrials.gov · NCT05977673 (opens the source filing in a new tab)
Trial
Study registered
Mar 1, 2024
Diffuse Large B Cell Lymphoma (DLBCL) · RECRUITING · sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna · An Italian Multicentric Retrospective Observational Study to Assess Effectiveness and Safety of the Combination of Tafasitamab and Lenalidomide in Diffuse Large B-cell Lymphoma Patients Treated Under Named Patient Program
ClinicalTrials.gov · NCT06782789 (opens the source filing in a new tab)
Trial
NA registered
May 11, 2023
Haematological Malignancy · RECRUITING · sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna · Safety and Feasibility of a Multidisciplinary Programme of Integrated Hospital-home Management With Early Discharge of Patients With Haematological Malignancies Undergoing High-dose Chemotherapy in Hospital
ClinicalTrials.gov · NCT06814405 (opens the source filing in a new tab)
Trial
NA registered
Nov 3, 2022
Hodgkin Lymphoma in Remission · RECRUITING · sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna · Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow up of Patients With Hodgkin's Lymphoma
ClinicalTrials.gov · NCT06761274 (opens the source filing in a new tab)
Trial
Study registered
Jun 6, 2022
Diffuse Large B Cell Lymphoma (DLBCL) · ACTIVE_NOT_RECRUITING · sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna · Pixantrone as Bridging Therapy to Allogenic Transplant or CAR-T Cell Therapy in DLBCL Patients
ClinicalTrials.gov · NCT06760936 (opens the source filing in a new tab)
Trial
Study registered
May 20, 2021
DLBCL - Diffuse Large B Cell Lymphoma · ACTIVE_NOT_RECRUITING · sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna · An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin Plus Rituximab (± Bendamustine) Under Named Patient Programme
ClinicalTrials.gov · NCT06734078 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 75%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase II trial registered: Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy
7mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy
7mo agoTrial recruitingSource (opens the source filing in a new tab)
Study registered, no phase assigned: Study to Assess Effectiveness and Safety of Zanubrutinib for Patients With Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)
Feb 2025Trial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Study to Assess Effectiveness and Safety of Zanubrutinib for Patients With Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)
Feb 2025Trial recruitingSource (opens the source filing in a new tab)
Study registered, no phase assigned: Safety and Feasibility of a Multidisciplinary Programme of Integrated Hospital-home Management With Early Discharge of Patients With Haematological Malignancies Undergoing High-dose Chemotherapy in Hospital
Feb 2025Trial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Safety and Feasibility of a Multidisciplinary Programme of Integrated Hospital-home Management With Early Discharge of Patients With Haematological Malignancies Undergoing High-dose Chemotherapy in Hospital
Feb 2025Trial recruitingSource (opens the source filing in a new tab)
Study registered, no phase assigned: An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin Plus Rituximab (± Bendamustine) Under Named Patient Programme
Jan 2025Trial registeredSource (opens the source filing in a new tab)
Study registered, no phase assigned: An Italian Multicentric Retrospective Observational Study to Assess Effectiveness and Safety of the Combination of Tafasitamab and Lenalidomide in Diffuse Large B-cell Lymphoma Patients Treated Under Named Patient Program
Jan 2025Trial registeredSource (opens the source filing in a new tab)
Trial now recruiting: An Italian Multicentric Retrospective Observational Study to Assess Effectiveness and Safety of the Combination of Tafasitamab and Lenalidomide in Diffuse Large B-cell Lymphoma Patients Treated Under Named Patient Program
Jan 2025Trial recruitingSource (opens the source filing in a new tab)
Study registered, no phase assigned: Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow up of Patients With Hodgkin's Lymphoma
Jan 2025Trial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow up of Patients With Hodgkin's Lymphoma
Jan 2025Trial recruitingSource (opens the source filing in a new tab)
Study registered, no phase assigned: Pixantrone as Bridging Therapy to Allogenic Transplant or CAR-T Cell Therapy in DLBCL Patients
Jan 2025Trial registeredSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Peer position

Grant to raise

Study registered

PHASE2 registered

Study registered

NA registered

NA registered

Study registered

Study registered